Lidocaine(Lignocaine) ๐
๐ Lignocaine (Lidocaine) is widely used as both a local anaesthetic and an antiarrhythmic drug. It should only be administered by, or under the direct supervision of, trained personnel with skills in anaesthesia and airway management. โ ๏ธ It must not be given parenterally without adequate resuscitation facilities available.
- โก Class Ib antiarrhythmic agent.
- ๐งช Rapidly hydrolysed in the gut and undergoes extensive first-pass metabolism in the liver โ therefore given IV (not orally).
Indications
- ๐ Ventricular tachycardia (VT).
- ๐ Ventricular fibrillation (VF).
- โ Not used in supraventricular tachycardia (SVT).
- โ Not recommended for non-sustained VT or ventricular ectopics (generally no treatment needed).
Cautions
- โ ๏ธ Heart block.
- โ ๏ธ Severe hepatic impairment (reduced metabolism โ toxicity risk).
Interactions
- ๐ See BNF for full list (notably interacts with other antiarrhythmics and drugs affecting hepatic metabolism).
Side Effects
- โค๏ธ Bradycardia, hypotension, asystolic arrest (with toxicity).
- ๐คข Nausea, vomiting, paraesthesia.
- โก Neurological: seizures, confusion, coma.
Dose
- CPR (when amiodarone unavailable or contraindicated):
Lidocaine 1โ2 mg/kg IV bolus (do not exceed 3 mg/kg in the first hour).
Typical dose: 50โ100 mg IV over 2โ5 minutes (โ1 mg/kg), followed by further boluses up to 200 mg within 30 min, then infusion.
- Ventricular Arrhythmias:
100 mg IV bolus over a few minutes โ followed by:
- IV infusion 4 mg/min for 30 min
- then 2 mg/min for 2 hours
- then 1 mg/min (reduce further if continued >24 hrs).
โ ๏ธ Requires ECG monitoring and specialist advice. Lidocaine bolus effect lasts ~15โ20 minutes.
References